Tisch MS News

The Tisch MS Research Center will close at 2:00pm today and remain closed through Monday, May 25th. We wish everyone a safe, happy, and healthy holiday weekend.

Interim Results Indicate Positive Efficacy Trends in FDA-Approved Phase I Clinical Stem Cell Trial             For Patients with Multiple Sclerosis

This week eight of Tisch MSRCNY’s researchers arrived in Washington, D.C. to attend the 67th American Academy of Neurology Annual Meeting. Eight of the Center’s Abstracts will be presented at the meeting. Dr. Sadiq was also informed on Monday that the preliminary results from our FDA-approved Phase 1 clinical stem cell trial for patients with MS were selected as a presentation during the Multiple Sclerosis Highlights in the Field session on Wednesday, April 22nd.

 

We are currently the only center in the United States that is conducting an FDA approved clinical trial

using stem cells in patients with MS. The goal of the Phase I trial is to determine whether or not the

Metabolomics is an emerging field of science that studies the collection of all metabolites in a biological system. Dr. Fozia Mir, Assistant Research Scientist at Tisch MS, presented a comprehensive overview of how metabolomic studies are currently being applied to MS research. Dr. Mir also presented her own exciting work describing the screening of metabolites in the cerebrospinal fluid from MS patients. Intriguingly, a number of metabolites were altered in different subsets of MS patients, highlighting several new metabolic pathways that may be altered during the disease.

Today, Dr. Saud A. Sadiq and Dr. Massimiliano Cristofanilli will present at a meeting held by the San Marino Foundation for the Research and Treatment of Autoimmune Diseases and the Sammarinese Association for Multiple Sclerosis in San Marino, organized by Dr. Susanna Guttmann, Chief Neurologist for the Institute of Health Care at San Marino. Attending the meeting will be San Marino’s highest ranking authorities on health care, Dr. Guttmann, neurologists and health care providers at the San Marino Association, as well as doctors and MS patients from Italy and multiple media agencies.

Two studies from the Tisch MS Center were selected by the American Academy of Neurology (AAN) Science Committee to be highlighted as a significant advance based on animal research. Congratulations to first authors Ruth-Anne Langan (Dr. Violaine Harris' group) and Dr. Marwan Alahiri (Dr. Ying Liu's group) for being selected. 

The stem cell research division of the Tisch MS Research Center of New York is pleased to announce the completed enrollment of 20 patients to participate in the phase I clinical trial investigating the safety and efficacy of autologous, mesenchymal stem cell-derived neural progenitors (MSC-NPs) for the treatment of multiple sclerosis. We are no longer recruiting for this study. Interim results of this clinical trial will be presented at upcoming scientific conferences and simultaneously announced on our website.

The American Academy of Neurology (AAN) recently announced that it accepted eight of the Tisch MS Research Center of New York’s research abstracts to be presented at its 2015 Annual Meeting. This year marks the AAN’s 67th Annual Meeting, which will be held April 18th – 25th at the Walter E. Washington Convention Center in Washington, DC. 

Congratulations to Dr. Saud A. Sadiq who has been recognized in Castle Connolly's "America's Top Doctors" 14th ed. and "Top Doctors: New York Metro Area" 18th ed.

Pages

Real Time Analytics